<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02980692</url>
  </required_header>
  <id_info>
    <org_study_id>CLR_16_23</org_study_id>
    <nct_id>NCT02980692</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of SUNPG1623</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Active Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Global FZE</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Global FZE</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to
      demonstrate the safety and efficacy of SUNPG1623
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2017</start_date>
  <completion_date type="Anticipated">May 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who achieve response</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve response</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Active Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>SUNPG1623 I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Short-term dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SUNPG1623 II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mid-term dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SUNPG1623 dose III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mid-term dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SUNPG1623 dose IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mid to long-term dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Mid to long-term dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUNPG1623 I</intervention_name>
    <description>injection</description>
    <arm_group_label>SUNPG1623 I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUNPG1623 II</intervention_name>
    <description>injection</description>
    <arm_group_label>SUNPG1623 II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUNPG1623 III</intervention_name>
    <description>injection</description>
    <arm_group_label>SUNPG1623 dose III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUNPG1623 IV</intervention_name>
    <description>injection</description>
    <arm_group_label>SUNPG1623 dose IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>injection</description>
    <arm_group_label>SUNPG1623 II</arm_group_label>
    <arm_group_label>SUNPG1623 dose III</arm_group_label>
    <arm_group_label>SUNPG1623 dose IV</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has provided written informed consent

          -  Subject is ≥ 18 years of age at time of Screening

          -  Subject must be on stable dose of NSAID for ≥ 4 weeks prior to initiation of IMP

          -  Subject has a negative evaluation for TB within 4 weeks before initiating IMP

        Exclusion Criteria:

          -  Subject has a planned surgical intervention between Baseline and the Week 24
             evaluation for a pretreatment condition

          -  Subject has an active infection or history of infections

          -  Subject has any concurrent medical condition or uncontrolled, clinically significant
             systemic disease

          -  Subject has a known history of infection with hepatitis B, hepatitis C, or human
             immunodeficiency virus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shravanti Bhowmik, MD</last_name>
    <phone>912266455645</phone>
    <email>shravanti.bhowmik@sparcmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SPARC Site 1</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2016</study_first_posted>
  <last_update_submitted>February 16, 2018</last_update_submitted>
  <last_update_submitted_qc>February 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

